An unexpected role of cholesterol sulfotransferase and its regulation in sensitizing mice to acetaminophen induced liver injury

Yunqi An, Pengcheng Wang, Pengfei Xu, Hung-Chun Tung, Yang Xie, Levent Kirisci, Meishu Xu, Songrong Ren, Xin Tian, Xiaochao Ma, Wen Xie[#]

Center for Pharmacogenetics and Department of Pharmaceutical Sciences (Y.A., P.W., P.X., H-C.T., Y.X., L.K., M.X., S.R., X.T., X.M., W.X.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pharmacy (X.T.), The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Pharmacology and Chemical Biology (W.X.), University of Pittsburgh, Pittsburgh, Pennsylvania

1

Running Title: SULT2B1b sensitizes mice to APAP toxicity

#**Corresponding Author:** Department of Pharmaceutical Sciences, 306 Salk Pavilion,

University of Pittsburgh, Pittsburgh, PA 15261. E-mail: wex6@pitt.edu

Number of text pages: 38

Number of figures: 5

Number of references: 48

Number of words in Abstract: 160

Number of words in Introduction: 750

Number of words in Discussion: 830

DISCLOSURE STATEMENT: The authors have nothing to disclose

Key words: sulfotransferase; HNF4α; acetaminophen; liver injury

Abbreviations:

ALF, acute liver failure; ALT, alanine aminotransferase; APAP, acetaminophen; APAP-CYS, APAP-cysteine; AST, aspartate aminotransferase; Fabp, fatty acid binding protein; GSH, glutathione; GST, glutathione *S*-transferase; HNF4α, hepatic nuclear factor 4α; KO, knockout; LXR, liver X receptor; NAPQI, N-acetyl-*p*-benzoquinone-imine; SULT, sulfotransferase; SULT2B1b, cholesterol sulfotransferase; TG, transgenic; UGT, UDP-glucuronosyltransferase

Abstract

Overdose of acetaminophen (APAP) is the leading cause of acute liver failure (ALF) in the United States. The sulfotransferase-mediated sulfation of APAP is widely believed to a protective mechanism to attenuate the hepatotoxicity of APAP. The cholesterol sulfotransferase SULT2B1b is best known for its activity in catalyzing the sulfoconjugation of cholesterol to synthesize cholesterol sulfate. SULT2B1b can be transcriptionally and positively regulated by the hepatic nuclear factor 4α (HNF4α). In this study, we uncovered an unexpected role for SULT2B1b in APAP toxicity. Hepatic overexpression of SULT2B1b sensitized mice to APAP-induced liver injury, whereas ablation of the Sult2B1b gene in mice conferred resistance to the APAP hepatotoxicity. Consistent with the notion that Sult2B1b is a transcriptional target of HNF4α, overexpression of HNF4α sensitizes mice or primary hepatocytes to APAP-induced hepatotoxicity in a Sult2B1b dependent manner. We conclude that the HNF4α-SULT2B1b axis has a unique role in APAP-induced acute liver injury, and SULT2B1b induction might be a risk factor for APAP hepatotoxicity.

Introduction

Acetaminophen (APAP) or Tylenol is a commonly used drug to reduce fever and relieve pain.

However, APAP overdoses result in approximately 500 people dead each year in the United

States (Lee, 2008). APAP overdose causes most of the acute liver failure (ALF), especially in the

United States (Furuta et al., 2016). At therapeutic doses, about 3% of APAP is excreted as the

parent drug via the urine. More than 90% of APAP can be rapidly metabolized into the nontoxic

compounds by phase II conjugating enzymes in the liver, two thirds through glucuronidation by

UDP-glucuronosyltransferases (UGTs) and one third through sulfation by sulfotransferases

(SULTs). 5%-9% of APAP is bioactivated to a highly reactive toxic metabolite, N-acetyl-p-

benzoquinone imine (NAPQI), by phase I cytochrome P450 enzymes (CYPs), especially the

CYP2E1 (Dahlin et al., 1984; Mannery et al., 2010; Potter et al., 1973). NAPQI has a short half-

life, because it can be rapidly eliminated by conjugation with glutathione (GSH), before being

excreted via the urine as mercapturic acid and cysteine conjugates (Du et al., 2016). When APAP

overdose occurs, the glucuronidation and sulfation pathways are saturated, so more APAP is

metabolized by CYPs to NAPQI. Excessive NAPQI depletes intracellular GSH. Accumulated

4

NAPQI binds to other cellular proteins, leading to mitochondrial oxidative stress, nuclear DNA

fragmentation, and hepatocyte death (Beger et al., 2015; Du et al., 2016). The oral formulation of

N-acetylcysteine (NAC) is an antidote approved for treating the overdose of APAP. NAC is

nearly fully hepatoprotective when it is administered to patients within 8 hours after an acute

APAP overdose (Wolf et al., 2007; Yoon et al., 2016). However, NAC has a narrow therapeutic

window (Nam et al., 2017). There are no effective treatment options for severe ALF except for

liver transplantation. Thus, new therapeutics that target APAP overdose are urgently needed.

The human SULT2 family, also called hydroxysteroid-SULT family, is comprised of two genes,

known as SULT2A1 and SULT2B1. They catalyze the sulfo-conjugation of many compounds

and differ in tissue distribution and substrate specificity (Falany and Rohn-Glowacki, 2013).

Because of the length of transcripts, SULT2B1 is divided into two isoforms, SULT2B1a and

SULT2B1b. At the transcript level, the expression of SULT2B1a and SULT2B1b is very similar,

but only the SULT2B1b protein can be detected in humans (Falany et al., 2006). SULT2B1b

appears to be the major functional SULT2B1 isoform. SULT2B1b is specific for the sulfation of

5

3-hydroxysteroids (Falany and Rohn-Glowacki, 2013). Subsequent studies have reported crucial

roles of SULT2B1b in regulating liver functions and impacting the pathogenesis of diseases.

SULT2B1b is induced by liver regeneration in a mouse model of partial hepatectomy (Lo Sasso

et al., 2010). SULT2B1b increases the proliferation of liver cancer cells which may have

contributed to the progression of HCC (Yang et al., 2013). Oxysterols, the endogenous ligands

for the liver X Receptor (LXR), are substrates of SULT2B1b (Bai et al., 2011; Bensinger et al.,

2008). Upregulation of SULT2B1b inhibited lipogenesis by sulfonating and deactivating the

LXR-activating oxysterols (Bai et al., 2011), and aggravated 3,5-diethoxycarbonyl-1,4-

dihydrocollidine (DDC)-induced liver damage by suppressing oxysterol-induced LXR activation

(Wang et al., 2017). SULT2B1b has been reported to be regulated by several nuclear receptors,

such as CAR (Dong et al., 2009), VDR (Seo et al., 2013), and PPARs (Jiang et al., 2005).

We recently reported that SULT2B1b can inhibit hepatic gluconeogenesis by suppressing the

gluconeogenic activity of hepatocyte nuclear factor 4α (HNF4α) (Shi et al., 2014). HNF4α

promotes gluconeogenesis by upregulating PEPCK and G6Pase gene expression (Rhee et al.,

2003). Mechanistically, SULT2B1b and its enzymatic product cholesterol sulfate suppress

gluconeogenesis by inhibiting acetyl-CoA synthetase (Acss) gene expression, leading to reduced

acetylation and nuclear exclusion of HNF4α (Shi et al., 2014). More recently, we reported that

the SULT2B1b itself is a transcriptional target gene of HNF4α (Bi et al., 2018). The

establishment of SULT2B1b as a HNF4α target gene called up our hypothesis that the induction

of SULT2B1b by HNF4α involves in a negative feedback to inhibit the gluconeogenic activity of

HNF4α (Bi et al., 2018). Although several SULT isoforms and their regulations have been

implicated in APAP toxicity (Saini et al., 2011), it is unknown whether SULT2B1b plays a role

in APAP hepatotoxicity and if so, whether HNF4α can also impact the hepatotoxicity of APAP

by its positive regulation of SULT2B1b.

In this study, we demonstrated that overexpression of hepatic SULT2B1b sensitized mice to

APAP-induced liver damage, whereas ablation of Sult2B1b attenuated mice from APAP toxicity.

A forced expression of Hnf4α aggravates APAP hepatotoxicity in a Sult2B1b dependent manner.

Our results pointed to SULT2B1b induction as a potential risk factor for APAP-induced acute

liver damage.

Materials and Methods

Animals. The Sult2B1b knockout mice (Strain # 018773) in C57BL/6J-129/SvJ mixed background were purchased from the Jackson Laboratory (Bar Harbor, ME), and wild type (WT) mice of the same mixed genetic background were used as the controls. The liver-specific FABP-SULT2B1b transgenic mice in the C57BL/6J background were created and characterized as previously described (Shi et al., 2014), and WT C57BL/6J mice were used as the controls. All mice used in this study were 6 to 8 weeks old female mice. The use of animals in this study complied with all relevant federal guidelines and institutional policies.

Induction of APAP-induced liver injury. APAP was dissolved in 0.5% methyl cellulose solution. Before receiving a single dose of 200 mg/kg APAP by gavage, all of the mice were fasted for 16 hours. Food was given back to mice three hours after the APAP treatment. The mice were sacrificed 24 hours post APAP treatment (Saini et al., 2011). Liver tissues and serum samples were collected for biochemical analysis and histology. All chemicals mentioned in this study were bought from Sigma (St. Louis, MO).

Histology. For hematoxylin and eosin (H&E) staining, liver samples were fixed in 10%

paraformaldehyde, embedded in paraffin, sectioned at 4 μm, and stained. For

immunohistochemistry analysis, standard immunohistochemical procedures were performed

using a Ki67 antibody purchased from Abcam (Cambridge, MA). APO-BRDU (TUNEL)

Apoptosis Kit from Novus (Littleton, CO) was used to examine dying cells with exposed or

fragmented DNA ends.

Serum and liver tissue chemistry. ALT and AST analysis in the serum (Lu et al., 2015) and

primary hepatocytes (Miyakawa et al., 2015) were performed using commercial assay kits from

Stanbio Laboratory (Boerne, TX). The ratio of ALT in the medium of primary hepatocytes to

ALT in the lysates of primary hepatocytes was calculated as the percentage of ALT release. The

concentrations of GSH and GSSG in the liver tissue samples were measured by Assay Kit from

BioAssay Systems (Hayward, CA).

10

Real-time PCR. Total RNA in the liver was isolated by the TRIzol reagent from Thermo Fisher

Scientific (Pittsburgh, PA). Reverse transcription was conducted with random hexamer primers

and Superscript RT III enzyme from Invitrogen. The ABI 7300 Real-Time PCR System was

used to perform SYBR Green-based real-time PCR. The quantity of mRNA measured was

normalized to the cyclophilin gene expression.

Western blot analysis. Western blotting was conducted as described previously (Shi et al.,

2014). The primary antibodies for Hnf4α (Cat # MA1-199) and Sult2B1b (sc-67103) were

ordered from Thermo Fisher Scientific and Santa Cruz (Santa Cruz, CA), respectively.

Isolation, culture and adenoviral infection of primary hepatocytes from mice. As described

previously (Jiang et al., 2014), primary hepatocytes were extracted from 8 to 10 weeks old mice.

Briefly, the mice liver was first perfused with Hanks' buffered salt solution containing 0.1 M

HEPES and 0.5 mM EGTA at the speed of 5 ml/min for 5–10 minutes and then perfused with L-

15 medium containing 20 mg/ml liberase, 1.8 mM $CaCl_2$, and 0.1 M HEPES from Roche

11

(Indianapolis, IN). When the perfusion was completed, the dissociated hepatocytes were filtered

through 50-mm tissue cell strainer and centrifuged at 500 rpm for 3 minutes at 4°C to collect.

Hepatocytes were seeded onto 6-well plates coated with type 1 collagen in William E medium

containing 5% fetal bovine serum. After 2 hours, the medium was replaced by HepatoZYME-

SFM medium (GIBCO, Grand Island, NY). To overexpress Hnf4α, the primary hepatocytes were

infected with adenovirus expressing Hnf4α (Ad-Hnf4α), or the control virus (Ad-Ctrl). Both

virus were given as presents by Dr. Yanqiao Zhang from the Northeast Ohio Medical University

(Yin et al., 2011).

APAP metabolic analysis. APAP metabolic analysis was performed as described (Cheng et al.,

2009). In brief, 100 mg of liver tissue samples were homogenized in 500 µl of water. 200 µl of

acetonitrile:methanol (1:1, v/v) was added to 100 µl of each homogenate. The mixture was

vortexed and centrifuged (15,000 g for 10 min), and the supernatant was transferred to a new

1.5mL Eppendorf vial for a second centrifugation (15,000 g for 10 min). 20 µl of the serum

samples were added by 80 µl of methanol. The prepared mixture was vortexed and centrifuged at

12

15,000 g for 10 min. Each supernatant from above was transferred to an autosampler vial and

analyzed by ultraperformance liquid chromatography coupled with time-of-flight mass

spectrometry (UPLC-TOFMS) from Waters Corporation (Milford, MA).   Metabolites was

separated by an Acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm; Waters, Milford, MA)

using a gradient ranging from 5% to 95% aqueous acetonitrile containing 0.1% formic acid over

a 6-min run. TOFMS was operated in positive mode with electrospray ionization and the MS

data were acquired in centroid format (50-1,000 Da). The capillary and cone voltages were set as

0.8 kV and 40 V, respectively. The source temperature was set as 150°C. The desolvation gas

(800 l/hour) was set at 500°C. APAP and its major metabolites (APAP-sulfate, APAP-

glucuronide, APAP-GSH, and APAP-Cys) were identified by high-resolution accurate mass and

tandem MS/MS fragmental analysis. The peak areas were quantified to represent the signal

intensities. All data were acquired using Masslynx™ V4.1 software and quantified using

Quanlynx™ V4.1 (Waters Corp., Milford, MA).

Statistical analysis. All the data are expressed as means ± standard error of the mean (SEM).

Comparisons of two groups were evaluated by the unpaired two-tailed Student's *t* test, and

comparisons of three or more groups were performed by one-way MANOVA. The MANOVA

analysis was carried out by SPSS version 24.0. to understand if there were differences between

the genotype on the two dependent variables, AST and ALT. The criterion for statistical

significance was a *P* value of less than 0.05 unless otherwise indicated. Some results were

applied Bonferroni correction to control the type 1 errors, and accepted a *P* value of less than

0.005 (for Figures 1 and 2, in which 10 comparisons were tested in the same samples), 0.017 (for

Figure 3, in which 3 comparisons were tested in the same samples), 0.003 (for Figure 5A-C, in

which 15 comparisons were tested in the same samples), 0.025 (for Figure 5E, in which 2

comparisons were tested in the same samples), or 0.01 (for Figure 5F, in which 5 comparisons

were tested in the same samples).

14

Results

Transgenic overexpression of SULT2B1b in the liver aggravates APAP-induced liver injury

The creation and characterization of transgenic (TG) mice that overexpress the cholesterol sulfotransferase (SULT2B1b) in the liver under the rat fatty acid binding protein (FABP) gene promoter were previously reported by us (Shi et al., 2014). To investigate whether SULT2B1b plays a role in APAP hepatotoxicity, we treated the TG mice with a single dose of APAP (200 mg/kg by gavage) after a 16-hour fasting (Saini et al., 2011). Twenty-four hours after the treatment, liver tissue and serum samples were harvested for analysis. H&E staining revealed that the livers of the TG mice displayed more severe damage compared to the wild type (WT) mice. The liver histology of the vehicle-treated TG mice appeared normal. Upon the APAP treatment, the TG mice showed a quantifiably more extensive necrotic liver damage than their WT counterparts (Fig. 1A). In addition, APAP-treated TG mice had elevated serum levels of alanine aminotransferase (ALT) (Fig. 1B) and aspartate aminotransferase (AST) (Fig. 1C) activity compared to APAP-treated WT mice. In APAP-induced liver injury, it is believed that

15

overdose of APAP is metabolized by CYPs to reactive intermediate NAPQI, which depletes

GSH, binds to cellular proteins and induces nuclear DNA fragmentation, leading to necrotic

hepatocyte death (Hinson et al., 2010). So, we assessed nuclear DNA fragmentation by TUNEL

staining. The TUNEL staining in APAP-treated TG mice was increased (Fig. 1D), consistent

with the increased liver damage in this genotype. It is known that liver regeneration is important

for survival after APAP overdose (Bhushan et al., 2014), because hepatic cell necrosis eventually

induces liver regeneration (Guicciardi et al., 2013). Usually, more necrosis is followed by more

cell proliferation. Therefore, we evaluated the expression of cell proliferation and cell cycle

related genes in the liver by real-time PCR. The expression of proliferating cell nuclear antigen

(*Pcna*) of TG mice was significantly higher than the WT mice (Fig. 1E), consistent with the

notion that TG mice had more liver damage than WT mice. Furthermore, the hepatic expression

of inflammatory cytokine genes interleukin-6 (*Il-6*) and interleukin-1β (*Il-1β*) in TG mice was

significantly higher than that in WT mice after the APAP treatment (Fig. 1F).

Ablation of Sult2B1b protects mice from APAP-induced liver damage

16

To assess whether Sult2B1b ablation affects APAP-induced liver injury, we treated Sult2B1b

knockout (KO) mice with a single dose of 200 mg/kg APAP. The KO mice showed less liver

damage compared to the WT mice. The WT mice showed remarkable necrotic liver damage at

24 hours post-APAP treatment as expected. In contrast, the KO mice showed less liver damage

as evidence by smaller necrotic area (Fig. 2A), decreased serum levels of ALT (Fig. 2B) and

AST (Fig. 2C), and decreased TUNEL staining (Fig. 2D). The mRNA expression of *Pcna* and

Ccnd 1 was significantly decreased in APAP-treated KO mice (Fig. 2E), consistent with an

attenuated liver injury in this genotype. The decreased hepatocyte proliferation in APAP-treated

KO mice was also supported by a decreased immunostaining of the hepatocyte proliferation

marker Ki67 (Fig. 2F). Consistently and compared to the WT mice, the mRNA expression of *Il-*

1β was decreased in APAP-treated KO mice (Fig. 2G).

Overexpression of Hnf4α induces Sult2B1b and sensitizes mice or primary hepatocytes to

APAP-induced injury

17

We recently reported that Sult2B1b is a transcriptional target of Hnf4α (Bi et al., 2018). Having

shown that overexpression of SULT2B1b was sufficient to sensitize mice to APAP-induced liver

injury, we wanted to determine whether up-regulation of Sult2B1b by HNF4α in the mouse liver

will have a similar sensitizing effect on APAP-induced liver injury. In this experiment, WT mice

were infected with adenovirus expressing Hnf4α (Ad-Hnf4α) or the control virus (Ad-Ctrl) for

one week before being treated with APAP. The overexpression Hnf4α and expected induction of

Sult2B1b were confirmed by Western blotting (Fig. 3A). Compared to Ad-Ctrl infected mice, the

Ad-Hnf4α infected mice displayed more severe liver injury as evidence by the gross appearance

and increased necrotic area (Fig. 3B), and increased serum levels of ALT and AST (Fig. 3C).

The in vivo results were further supported by in vitro results using primary hepatocytes isolated

from WT mice. In this experiment, primary hepatocytes infected with Ad-Ctrl or Ad-Hnf4α were

treated with 5 mM APAP for 24 hours. The overexpression of Hnf4α and induction of Sult2B1b

were proved by real-time PCR (Fig. 3D). Compared to Ad-Ctrl infected hepatocytes, Ad-Hnf4α

infected hepatocytes showed an increased APAP-responsive release of ALT (Fig. 3E), and a

decreased cell viability as shown by the MTT assay (Fig. 3F).

The sensitizing effect of HNF4α on APAP-induced injury is Sult2B1b dependent

To determine whether the sensitizing effect of HNF4α on APAP-induced liver injury in vivo is

Sult2B1b dependent, we infected Sult2B1b KO mice with Ad-Ctrl or Ad-Hnf4α before

challenging them with APAP. The overexpression of Hnf4α was verified by Western blotting

(Fig. 4A). Upon the APAP treatment, the injury between Ad-Ctrl infected and Ad-Hnf4α

infected KO mice was not different, because neither the gross appearance and necrotic area (Fig.

4B), nor the serum levels of ALT and AST (Fig. 4C) were different between these two groups of

KO mice. The dependence of Sult2B1b in the sensitizing effect of Hnf4α was also confirmed in

primary hepatocytes isolated from the KO mice. The adenoviral overexpression of Hnf4α in KO

primary hepatocytes was confirmed by real-time PCR (Fig. 4D). The KO primary hepatocytes

infected with Ad-Ctrl or Ad-Hnf4α showed comparable release of ALT (Fig. 4E) and cell

viability as shown by the MTT assay (Fig. 4F). These results suggested that the sensitizing effect

of HNF4α on APAP-induced injury is Sult2B1b dependent both in vivo and in vitro.

Mechanism by which SULT2B1b sensitizes mice to APAP-induced liver injury

To understand the mechanism by which SULT2B1b sensitizes mice to APAP-induced liver

injury, we profiled the expression of genes known to play a role in APAP hepatotoxicity. Among

the phase I and phase II enzymes, only the expression of Ugt1 was dramatically induced in

APAP-treated TG mice, while the expressions of other APAP metabolizing enzymes showed no

significant difference in either the TG or KO mice (Fig. 5A). The expression of a panel of

nuclear receptors that are known to play a role in APAP hepatotoxicity, including CAR (Zhang

et al., 2002), FXR (Lee et al., 2010), LXRα (Saini et al., 2011), PXR (Guo et al., 2004) and RXR

(Dai et al., 2005), was not affected by the SULT2B1b transgene or knockout either (Fig. 5B). We

have previously reported that activation of LXRα attenuated APAP-induced liver injury (Saini et

al., 2011). We found the expressions of LXR as well as its target genes were not affected in

APAP-treated TG or KO mice (Fig. 5C). The total hepatic GSH content in APAP-treated TG

mice was remarkably decreased, whereas the ratio of GSSG/GSH was significantly increased in

TG mice (Fig. 5D, top), consistent with the increased sensitivity to APAP-induced liver injury in

this genotype. However, the total GSH level and the GSSG/GSH ratio between WT and KO

20

mice were not different (Fig. 5D, bottom). When the APAP metabolites were analyzed, we found

the serum concentrations of APAP-sulfate and APAP-glucuronide were increased in TG mice 24

hours after the APAP treatment (Fig. 5E), consistent with the expression of the SULT transgene

and induction of Ugt1 in this genotype. Interestingly, at 1 hour post-APAP treatment, the

transgene had little effect on the hepatic concentrations of parent APAP, APAP-sulfate, APAP-

glucuronide, APAP-GSH, or APAP-Cys (Fig. 5F).

Discussion

Overdose of APAP could eventually lead to acute liver failure. Although the mechanisms of

APAP-induced liver injury have been extensively studied, factors that can affect the progression

of APAP-induced liver disease or improve the liver recovery are less investigated. Identification

of the related pathogenic factors will provide novel therapeutic approaches for the treatment of

APAP overdose.

SULT2B1b is a hydroxysteroid sulfotransferase that plays important roles in diverse cell types

and tissues, such as suppressing lipogenesis (Ren and Ning, 2014) and gluconeogenesis (Bi et al.,

2018; Shi et al., 2014), and promoting the hepatocyte proliferation (Yang et al., 2013), affecting

prostate and colorectal cancer cells (Vickman et al., 2016), and suppressing the T cell receptor

signaling (Wang et al., 2016). In this study, we found a novel function of SULT2B1b in APAP-

induced liver toxicity. Specifically, hepatic transgenic overexpression of SULT2B1b exacerbated

APAP-induced acute liver injury, whereas ablation of the Sult2B1b gene in mice conferred

protection to APAP hepatotoxicity. The sensitizing effect of SULT2B1b on APAP-induced liver

22

injury is a surprise, considering that sulfation of APAP has been established as an important

mechanism for the detoxification of APAP. For example, we have previously reported the

attenuation of APAP toxicity by the activation LXRα (Saini et al., 2011), which was associated

with the induction of Sult2a1.

The mechanism by which SULT2B1b sensitizes mice to APAP toxicity remains to be clearly

defined. APAP may not be a substrate of SULT2B1b in vitro, according to a published report

(Yamamoto et al., 2015). However, we cannot exclude the possibility that APAP at our used

pharmacological concentrations is a substrate of SULT2B1b in vivo, a notion supported by the

increased serum concentration of APAP-sulfate in TG mice 24 hours after the APAP treatment

(Fig. 5E). Knowing that SULT2B1b suppresses LXR activity by sulfonating and deactivating the

endogenous LXR agonists (Bensinger et al., 2008; Villablanca et al., 2010), and activation of

LXR accelerates APAP clearance and attenuates APAP toxicity (Saini et al., 2011), we initially

hypothesized that the sensitizing effect of SULT2B1b might be due to the inhibition of LXR.

However, we found the expression of LXRα and its primary target genes was not affected by the

23

transgene (Fig. 5C). SULT2B1b transgene or ablation also had little effect on the expression of a

panel of nuclear receptors and CYP enzymes that are known to impact APAP metabolism and

toxicity, except that Ugt1 was up-regulated in APAP-treated TG mice for a yet to be defined

reason (Fig. 5). The decreased GSH level in APAP-treated TG mice (Fig. 5D) suggested that

overexpression of SULT2B1b may have compromised the replenishment of GSH via a yet to be

characterized mechanism. The hepatic concentrations of parent APAP, APAP-sulfate, APAP-

glucuronide and APAP-Cys at 1 hour post-APAP treatment showed no difference between the

WT and TG mice. The serum concentrations of two nontoxic metabolites APAP-sulfate and

APAP-glucuronide were elevated at 24 hours post-APAP in the TG mice, but they were not

affected in the KO mice. These results indicate that the effect of the SULT2B1b transgene on

APAP metabolism might be time dependent. A future detailed pharmacokinetic analysis is

necessary to conclude the effect of SULT2B1b on APAP metabolism.

The sensitizing effect of HNF4α is also intriguing. On one hand, the sensitization was

predictable based on the positive regulation of Sult2B1b by HNF4α as we have recently reported

24

(Bi et al., 2018), and the sensitizing effect of HNF4α was Sult2B1b dependent (Fig. 4). On the

other hand, the aggravation of APAP-induced liver injury by HNF4α was a surprise, considering

the reported hepatoprotective effect of HNF4α in liver injury induced by xenobiotic toxicants

(Beggs et al., 2016), alcohol and MCD diet (Xu et al., 2016), as well as in the context of NASH,

ALF and HCC (Baciu et al., 2017; Hang et al., 2017; Shi et al., 2014; Vallianou et al., 2016). To

our knowledge, it is the first demonstration that HNF4α aggravated APAP-induced liver injury

through its transcriptional regulation of SULT2B1b. It has been reported that HNF4α is critically

involved in PXR- and CAR-mediated transcriptional activation of CYP3A (Tirona et al., 2003),

and activation of PXR and CAR and the induction of CYP3A are known to sensitize mice to

APAP toxicity (Cheng et al., 2009; Guo et al., 2004; Zhang et al., 2002). Although the

expression of PXR, CAR and Cyp3a11 was not affected in APAP-treated TG or KO mice, we

cannot exclude the possibility that PXR, CAR and Cyp3a may play a role in mediating the

sensitizing effect of HNF4α on APAP toxicity. Female mice were used in this study. Our study

focused on APAP toxicity in terms of its metabolism. It has been reported that APAP

metabolism does not contribute to gender difference in the event of APAP overdose (Dai et al., 2006). Further studies are needed to prove whether the phenotype is sex specific.

In summary, we have uncovered a novel function of SULT2B1b and its regulation by HNF4α in APAP-induced acute liver injury. Our results suggest that SULT2B1b induction might be a risk factor for APAP hepatotoxicity. This notion is consistent with the report that nonalcoholic fatty liver disease (NAFLD) sensitized rodents to APAP-induced liver injury (Michaut et al., 2014), because NAFLD and its associated metabolic liver disease induce the hepatic expression of Sult2B1b (Shi et al., 2014).

Author contributions

Participated in research design: An and Xie.

Conducted experiments: An, Wang, P Xu, Tung, M Xu, Ren and Tian.

Performed data analysis: An, Wang, Y. Xie, Kirisci, and W. Xie.

Wrote or contributed to the writing of the manuscript: An, Ma and Xie.

26

Acquired funding: Xie.

References

Baciu C, Pasini E, Angeli M, Schwenger K, Afrin J, Humar A, Fischer S, Patel K, Allard J and Bhat M (2017) Systematic integrative analysis of gene expression identifies HNF4A as the central gene in pathogenesis of non-alcoholic steatohepatitis. *PLoS One* **12**(12): e0189223.

Bai Q, Xu L, Kakiyama G, Runge-Morris MA, Hylemon PB, Yin L, Pandak WM and Ren S (2011) Sulfation of 25-hydroxycholesterol by SULT2B1b decreases cellular lipids via the LXR/SREBP-1c signaling pathway in human aortic endothelial cells. *Atherosclerosis* **214**(2): 350-356.

Beger RD, Bhattacharyya S, Yang X, Gill PS, Schnackenberg LK, Sun J and James LP (2015) Translational biomarkers of acetaminophen-induced acute liver injury. *Arch Toxicol* **89**(9): 1497-1522.

Beggs KM, McGreal SR, McCarthy A, Gunewardena S, Lampe JN, Lau C, Apte U (2016) The role of hepatocyte nuclear factor 4-alpha in perfluorooctanoic acid- and perfluorooctanesulfonic acid-induced hepatocellular dysfunction. *Toxicol Appl Pharmacol* **304**:18-29.

Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, Shih R, Parks JS, Edwards PA, Jamieson BD and Tontonoz P (2008) LXR signaling couples sterol metabolism to proliferation in the acquired immune response. *Cell* **134**(1): 97-111.

Bhushan B, Walesky C, Manley M, Gallagher T, Borude P, Edwards G, Monga SP and Apte U (2014) Pro-regenerative signaling after acetaminophen-induced acute liver injury in mice identified using a novel incremental dose model. *Am J Pathol* **184**(11): 3013-3025.

Bi Y, Shi X, Zhu J, Guan X, Garbacz WG, Huang Y, Gao L, Yan J, Xu M, Ren S, Ren S, Liu Y, Ma X, Li S and Xie W (2018) Regulation of cholesterol sulfotransferase SULT2B1b by HNF4alpha constitutes a negative feedback control of hepatic gluconeogenesis. *Mol Cell Biol*.

Cheng J, Ma X, Krausz KW, Idle JR and Gonzalez FJ (2009) Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. *Drug Metab Dispos* **37**(8): 1611-1621.

Dahlin DC, Miwa GT, Lu AY and Nelson SD (1984) N-acetyl-p-benzoquinone imine: a

cytochrome P-450-mediated oxidation product of acetaminophen. *Proc Natl Acad Sci U S A* **81**(5): 1327-1331.

Dai G, Chou N, He L, Gyamfi MA, Mendy AJ, Slitt AL, Klaassen CD and Wan YJ (2005) Retinoid X receptor alpha Regulates the expression of glutathione *S*-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver. *Mol Pharmacol* **68**(6): 1590-1596.

Dai G, He L, Chou N, Wan YJ (2006) Acetaminophen metabolism does not contribute to gender difference in its hepatotoxicity in mouse. *Toxicol Sci* **92**(1): 33-41.

Dong B, Saha PK, Huang W, Chen W, Abu-Elheiga LA, Wakil SJ, Stevens RD, Ilkayeva O, Newgard CB, Chan L and Moore DD (2009) Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. *Proc Natl Acad Sci U S A* **106**(44): 18831-18836.

Du K, Ramachandran A and Jaeschke H (2016) Oxidative stress during acetaminophen hepatotoxicity: sources, pathophysiological role and therapeutic potential. *Redox Biol* **10**: 148-156.

Falany CN, He D, Dumas N, Frost AR and Falany JL (2006) Human cytosolic sulfotransferase 2B1: isoform expression, tissue specificity and subcellular localization. *J Steroid Biochem Mol Biol* **102**(1-5): 214-221.

Falany CN and Rohn-Glowacki KJ (2013) SULT2B1: unique properties and characteristics of a hydroxysteroid sulfotransferase family. *Drug Metab Rev* **45**(4): 388-400.

Furuta K, Yoshida Y, Ogura S, Kurahashi T, Kizu T, Maeda S, Egawa M, Chatani N, Nishida K, Nakaoka Y, Kiso S, Kamada Y and Takehara T (2016) Gab1 adaptor protein acts as a gatekeeper to balance hepatocyte death and proliferation during acetaminophen-induced liver injury in mice. *Hepatology* **63**(4): 1340-1355.

Guicciardi ME, Malhi H, Mott JL and Gores GJ (2013) Apoptosis and necrosis in the liver. *Compr Physiol* **3**(2): 977-1010.

Guo GL, Moffit JS, Nicol CJ, Ward JM, Aleksunes LA, Slitt AL, Kliewer SA, Manautou JE and Gonzalez FJ (2004) Enhanced acetaminophen toxicity by activation of the pregnane X receptor. *Toxicol Sci* **82**(2): 374-380.

Hang H-L, Liu X-Y, Wang H-T, Xu N, Bian J-M, Zhang J-J, Xia L and Xia Q (2017) Hepatocyte

nuclear factor 4A improves hepatic differentiation of immortalized adult human hepatocytes and improves liver function and survival. *Exp Cell Res* **360**(2): 81-93.

Hinson JA, Roberts DW and James LP (2010) Mechanisms of acetaminophen-induced liver necrosis. *Handb Exp Pharmacol* **196:** 369-405.

Jiang M, He J, Kucera H, Gaikwad NW, Zhang B, Xu M, O'Doherty RM, Selcer KW and Xie W (2014) Hepatic overexpression of steroid sulfatase ameliorates mouse models of obesity and type 2 diabetes through sex-specific mechanisms. *J Biol Chem* **289**(12): 8086-8097.

Jiang YJ, Kim P, Elias PM and Feingold KR (2005) LXR and PPAR activators stimulate cholesterol sulfotransferase type 2 isoform 1b in human keratinocytes. *J Lipid Res* **46**(12): 2657-2666.

Lee FY, de Aguiar Vallim TQ, Chong HK, Zhang Y, Liu Y, Jones SA, Osborne TF and Edwards PA (2010) Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity. *Mol Endocrinol* **24**(8): 1626-1636.

Lee WM (2008) Acetaminophen-related acute liver failure in the United States. *Hepatol Res* **38 Suppl 1**: S3-8.

Lo Sasso G, Celli N, Caboni M, Murzilli S, Salvatore L, Morgano A, Vacca M, Pagliani T, Parini P and Moschetta A (2010) Down-regulation of the LXR transcriptome provides the requisite cholesterol levels to proliferating hepatocytes. *Hepatology* **51**(4): 1334-1344.

Lu P, Yan J, Liu K, Garbacz WG, Wang P, Xu M, Ma X and Xie W (2015) Activation of aryl hydrocarbon receptor dissociates fatty liver from insulin resistance by inducing fibroblast growth factor 21. *Hepatology* **61**(6): 1908-1919.

Mannery YO, Ziegler TR, Park Y and Jones DP (2010) Acetaminophen elimination half-life in humans is unaffected by short-term consumption of sulfur amino acid-free diet. *J Pharmacol Exp Ther* 333(3): 948-953.

Michaut A, Moreau C, Robin MA, Fromenty B (2014) Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. *Liver Int* **34**(7): e171-179.

Miyakawa K, Albee R, Letzig LG, Lehner AF, Scott MA, Buchweitz JP, James LP, Ganey PE and Roth RA (2015) A Cytochrome P450-Independent Mechanism of Acetaminophen-Induced Injury in Cultured Mouse Hepatocytes. *J Pharmacol Exp Ther* **354**(2): 230-237.

Nam EJ, Hayashida K, Aquino RS, Couchman JR, Kozar RA, Liu J and Park PW (2017)

Syndecan-1 limits the progression of liver injury and promotes liver repair in acetaminophen-induced liver injury in mice. *Hepatology* **66**(5): 1601-1615.

Potter WZ, Davis DC, Mitchell JR, Jollow DJ, Gillette JR and Brodie BB (1973) Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. *J Pharmacol Exp Ther* **187**(1): 203-210.

Ren S and Ning Y (2014) Sulfation of 25-hydroxycholesterol regulates lipid metabolism, inflammatory responses, and cell proliferation. *Am J Physiol Endocrinol Metab* **306**(2): E123-130.

Rhee J, Inoue Y, Yoon JC, Puigserver P, Fan M, Gonzalez FJ and Spiegelman BM (2003) Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. *Proc Natl Acad Sci U S A* **100**(7): 4012-4017.

Saini SP, Sonoda J, Xu L, Toma D, Uppal H, Mu Y, Ren S, Moore DD, Evans RM and Xie W (2004) A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. *Mol Pharmacol* **65**(2): 292-300.

Saini SP, Zhang B, Niu Y, Jiang M, Gao J, Zhai Y, Hoon Lee J, Uppal H, Tian H, Tortorici MA, Poloyac SM, Qin W, Venkataramanan R and Xie W (2011) Activation of liver X receptor increases acetaminophen clearance and prevents its toxicity in mice. *Hepatology* **54**(6): 2208-2217.

Seo YK, Mirkheshti N, Song CS, Kim S, Dodds S, Ahn SC, Christy B, Mendez-Meza R, Ittmann MM, Abboud-Werner S and Chatterjee B (2013) SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer. *Mol Endocrinol* **27**(6): 925-939.

Shi X, Cheng Q, Xu L, Yan J, Jiang M, He J, Xu M, Stefanovic-Racic M, Sipula I, O'Doherty RM, Ren S and Xie W (2014) Cholesterol sulfate and cholesterol sulfotransferase inhibit gluconeogenesis by targeting hepatocyte nuclear factor 4alpha. *Mol Cell Biol* **34**(3): 485-497.

Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, Gonzalez FJ, Schuetz EG and Kim RB (2003) The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. *Nat Med* **9**(2):

220-224.

Vallianou I, Dafou D, Vassilaki N, Mavromara P and Hadzopoulou-Cladaras M (2016) Hepatitis C virus suppresses Hepatocyte Nuclear Factor 4 alpha, a key regulator of hepatocellular carcinoma. *Int J Biochem Cell Biol* **78**: 315-326.

Vickman RE, Crist SA, Kerian K, Eberlin L, Cooks RG, Burcham GN, Buhman KK, Hu CD, Mesecar AD, Cheng L and Ratliff TL (2016) Cholesterol Sulfonation Enzyme, SULT2B1b, Modulates AR and Cell Growth Properties in Prostate Cancer. *Mol Cancer Res* **14**(9): 776-786.

Villablanca EJ, Raccosta L, Zhou D, Fontana R, Maggioni D, Negro A, Sanvito F, Ponzoni M, Valentinis B, Bregni M, Prinetti A, Steffensen KR, Sonnino S, Gustafsson JA, Doglioni C, Bordignon C, Traversari C and Russo V (2010) Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. *Nat Med* **16**(1): 98-105.

Wang F, Beck-Garcia K, Zorzin C, Schamel WW and Davis MM (2016) Inhibition of T cell receptor signaling by cholesterol sulfate, a naturally occurring derivative of membrane cholesterol. *Nat Immunol* **17**(7): 844-850.

Wang Z, Yang X, Chen L, Zhi X, Lu H, Ning Y, Yeong J, Chen S, Yin L, Wang X and Li X (2017) Upregulation of hydroxysteroid sulfotransferase 2B1b promotes hepatic oval cell proliferation by modulating oxysterol-induced LXR activation in a mouse model of liver injury. *Arch Toxicol* **91**(1): 271-287.

Wolf SJ, Heard K, Sloan EP, Jagoda AS and American College of Emergency P (2007) Clinical policy: critical issues in the management of patients presenting to the emergency department with acetaminophen overdose. *Ann Emerg Med* **50**(3): 292-313.

Xu J, Xu Y, Li Y, Jadhav K, You M, Yin L, Zhang Y (2016) Carboxylesterase 1 is regulated by hepatocyte nuclear factor 4α and protects against alcohol- and MCD diet-induced liver injury. *Sci Rep* **6**:24277.

Yamamoto A, Liu MY, Kurogi K, Sakakibara Y, Saeki Y, Suiko M, Liu MC (2015) Sulphation of acetaminophen by the human cytosolic sulfotransferases: a systematic analysis. J Biochem **158**(6):497-504.

Yang X, Xu Y, Guo F, Ning Y, Zhi X, Yin L and Li X (2013) Hydroxysteroid sulfotransferase

SULT2B1b promotes hepatocellular carcinoma cells proliferation in vitro and in vivo. *PLoS One* **8**(4): e60853.

Yin L, Ma H, Ge X, Edwards PA and Zhang Y (2011) Hepatic hepatocyte nuclear factor 4alpha is essential for maintaining triglyceride and cholesterol homeostasis. *Arterioscler Thromb Vasc Biol* **31**(2): 328-336.

Yoon E, Babar A, Choudhary M, Kutner M and Pyrsopoulos N (2016) Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update. *J Clin Transl Hepatol* **4**(2): 131-142.

Zhang J, Huang W, Chua SS, Wei P and Moore DD (2002) Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. *Science* **298**(5592): 422-424.

Footnotes

Figure legends

Figure 1. Transgenic overexpression of SULT2B1b in the liver aggravates APAP-induced

liver injury. (**A**) Representative H&E staining on liver paraffin sections from WT and

SULT2B1b TG mice treated with vehicle (left, original magnification ×100) or APAP (middle,

original magnification ×100) for 24 hours. Shown on the right is enlarged view of boxed region

in middle panels highlighting the APAP-induced centrilobular necrosis. Shown on the bottom

left is the quantification of the necrotic areas. n=5 per group. (**B and C**) Serum levels of ALT (B)

and AST (C) in WT and TG mice treated with vehicle or APAP. (**D**) Representative images of

TUNEL staining in liver sections from WT and TG mice at 24 hours after the vehicle or APAP

treatment (original magnification ×200). (**E**) Relative hepatic mRNA expression of *Pcna*, *Ki67*,

C-myc, *Ccnd1*, and *Ccne1*. (**F**) Relative hepatic mRNA expression of *Il-6* and *Il-1β*. Data are

expressed as mean ± SEM. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.005$ (considered statistically

significant) upon Bonferroni correction, compared to WT within the same drug treatment (B and

C) or the same gene (E and F) as labeled.

Figure 2. Ablation of Sult2B1b protects mice from APAP-induced liver injury. (**A**)

Representative H&E staining on liver paraffin sections from WT and Sult2B1b KO mice treated

with vehicle (left, original magnification ×100) or APAP (middle, original magnification ×100)

for 24 hours. Shown on the right is enlarged view of boxed region in middle panels highlighting

the APAP-induced centrilobular necrosis. Shown on the bottom left is the quantification of the

necrotic areas. n=3 for WT-vehicle and KO-vehicle, n=8 for WT-APAP and KO-APAP. (**B and**

C) Serum levels of ALT (B) and AST (C) in WT and KO mice treated with vehicle or APAP.

(**D**) Representative images of TUNEL staining in liver sections from WT and KO mice at 24

hours after the vehicle or APAP treatment (original magnification ×200). (**E**) Relative hepatic

mRNA expression of *Pcna*, *Ki67*, *C-myc*, *Ccnd1*, and *Ccne1*. (**F**) The expression of Ki67 was

detected by immunohistochemistry with arrows indicating the positive stainings. (**G**) Relative

hepatic mRNA expression of *Il-6* and *Il-1β*. Data are expressed as mean ± SEM. *, $P < 0.05$; **,

$P < 0.01$; ***, $P < 0.005$ (considered statistically significant) upon Bonferroni correction,

compared to WT within the same drug treatment (B and C) or the same gene (E and G) as

labeled.

Figure 3. Overexpression of Hnf4α induces Sult2B1b and sensitizes mice or primary hepatocytes to APAP-induced injury. (**A**) Hepatic expression of Sult2B1b and Hnf4α in WT mice infected with Ad-Ctrl or Ad-Hnf4 and treated with APAP was measured by Western blot analysis. n=3 per group. (**B**) Representative gross appearance (top) and H&E staining on liver paraffin sections of Ad-Ctrl+APAP and Ad-Hnf4+APAP WT mice (middle, original magnification ×100), and enlarged view of boxed region in middle panels highlighting the APAP-induced centrilobular necrosis (bottom). Shown below is the quantification of the necrotic areas. n=3 for Ad-Ctrl, n=5 for Ad-Hnf4. (**C**) Serum levels of ALT and AST in WT mice infected with Ad-Ctrl or Ad-Hnf4α. (**D**) The mRNA expression of Hnf4α and Sult2B1b in WT primary hepatocytes infected with Ad-Ctrl or Ad-Hnf4α. (**E**) The percentage of ALT release from WT primary hepatocytes infected with Ad-Ctrl or Ad-Hnf4α and treated with 5 mM APAP for 24 hours. (**F**) MTT assay on primary hepatocytes described in (E). Data are expressed as mean ± SEM. *, $P < 0.05$, **, $P < 0.017$ (considered statistically significant) upon Bonferroni correction, all compared to Ad-Ctrl as labeled.

Figure 4. The sensitizing effect of HNF4α on APAP-induced injury is Sult2B1b dependent.

(**A**) Hepatic expression of Sult2B1b in Sult2B1b KO mice infected with Ad-Ctrl or Ad-Hnf4 and

treated with APAP was measured by Western blot analysis. n=3 per group. (**B**) Representative

gross appearance (top) and H&E staining on liver paraffin sections of Ad-Ctrl+APAP and Ad-

Hnf4+APAP KO mice (middle, original magnification ×100), and enlarged view of boxed region

in middle panels highlighting the APAP-induced centrilobular necrosis (bottom). Shown below

is the quantification of the necrotic areas. n=3 for Ad-Ctrl, n=5 for Ad-Hnf4. (**C**) Serum levels of

ALT and AST in KO mice infected with Ad-Ctrl or Ad-Hnf4α. (**D**) The mRNA expression of

Hnf4α in KO primary hepatocytes infected with Ad-Ctrl or Ad-Hnf4α. (**E**) The percentage of

ALT release from KO primary hepatocytes infected with Ad-Ctrl or Ad-Hnf4α and treated with

5 mM APAP for 24 hours. (**F**) MTT assay on primary hepatocytes described in (E). Data are

expressed as mean ± SEM. n.s., statistically not significant, all compared to Ad-Ctrl as labeled.

Figure 5. Mechanism by which SULT2B1b sensitizes mice to APAP-induced liver injury.

(**A and B**) Relative mRNA expression of a panel of Phase I and Phase II enzymes (**A**) and a

panel of nuclear receptors (**B**) in the livers of WT, SULT2B1b TG and KO mice treated with

APAP. n=3 per group. (**C**) Relative mRNA expression of *LXRα* and its target genes *Fas*, *Scd1*

and *Srebp-1c* in livers from WT, TG and KO mice treated with APAP. n=3 per group. (**D**)Total

liver GSH content and GSSG/GSH ratio in WT, TG and KO mice treated with APAP. n=3 per

group. (**E**) The contents of APAP-sulfate and APAP-glucuronide in the serum from WT and TG

mice at 24 hours after the APAP treatment. n=3 per group. (**F**) The contents of parent APAP,

APAP-sulfate, APAP-glucuronide and APAP-Cys in the liver from WT and TG mice at 1 hour

post-APAP treatment. n=3 per group. Data are expressed as mean $\pm$ SEM. *, $P < 0.05$; **, $P <$

0.01; ***, $P < 0.003$ (considered statistically significant) upon Bonferroni correction for (A), (B)

and (C); *, $P < 0.05$; **, $P < 0.01$ (considered statistically significant) for (D); *, $P < 0.05$, **, P

< 0.025 (considered statistically significant) upon Bonferroni correction for (E); and *, $P < 0.01$

(considered statistically significant) upon Bonferroni correction for (F); n.s., statistically not

significant, all compared to WT-APAP within the same gene (A-C) or the same parameter (D-F)

as labeled.

Figure 1

**Figure 2**

Figure 3

Figure 4

Figure 5